Notes
The study was funded by AstraZeneca Nordic-Baltic, Sweden.
Reference
Sabale U, et al. Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden. PharmacoEconomics-Open : 1 Jun 2017. Available from: URL: http://dx.doi.org/10.1007/s41669-017-0031-6
Rights and permissions
About this article
Cite this article
Fulvestrant 500mg cost-effective option in advanced breast cancer. PharmacoEcon Outcomes News 780, 18 (2017). https://doi.org/10.1007/s40274-017-4070-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4070-0